Core Viewpoint - A class action securities lawsuit has been filed against agilon health, inc. (AGL) for alleged securities fraud affecting investors between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding the company's 2025 guidance, which was deemed unachievable due to known industry challenges [1] - It is alleged that defendants overstated the financial benefits from strategic actions taken by agilon to mitigate risks, leading to materially false and misleading statements about the company's business and prospects [1] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until March 2, 2026, to request appointment as lead plaintiff, with no costs or obligations to participate in the lawsuit [1] - Levi & Korsinsky, LLP, the law firm handling the case, has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [1]

Oracle Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 6, 2026 to Discuss Your Rights - ORCL [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Oracle Corporation ("Oracle" or the "Company") (NYSE: ORCL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Oracle investors who were adversely affected by alleged securities fraud between June 12, 2 ...

Core Insights - Unisys will participate as a gold sponsor in the 2026 Cybersecurity Summit, focusing on strategies for operational resilience and risk reduction in cybersecurity [1] - Philip Swarbrick, Unisys's VP of cybersecurity solutions, will discuss the impact of AI on threat detection and risk management during the panel session titled "AI and Emerging Tech at the 2026 Security Frontline" [1] - Research from Unisys indicates that fewer than 15% of organizations are adopting a proactive cybersecurity approach, highlighting the need for stronger defenses against emerging threats [1] Event Details - The Cybersecurity Summit will take place on February 25, 2026, at the Sheraton New York Times Square Hotel, with the panel discussion scheduled for 11:30 a.m. EST [1] - The session will address how AI is reshaping risk mitigation and the challenges posed by generative systems and data integrity [1] Industry Context - The cybersecurity landscape is evolving, with increasing risks such as data privacy breaches and social engineering, necessitating collaboration within the industry to enhance defenses [1] - Unisys emphasizes the importance of adopting robust cybersecurity measures to address sophisticated challenges introduced by AI technologies [1]

Core Viewpoint - Stellantis NV is under investigation for potentially misleading public statements regarding its electric vehicle (EV) programs, following a significant financial charge and acknowledgment of overly optimistic market assumptions [1]. Group 1: Financial Impact - On February 6, 2026, Stellantis disclosed a charge of €22–22.2 billion related to its EV rollout, indicating a major financial setback [1]. - Following the announcement, Stellantis shares fell approximately 28% in a single trading session, marking one of the worst trading days in the company's history [1]. Group 2: Market Reactions - Prior to the February 6 disclosure, multiple downgrades occurred: Wall Street Zen downgraded STLA to Sell on January 31, 2026, and Morgan Stanley downgraded it to Equal-Weight on February 3, 2026, citing an "investment lag" [1]. - A report on February 5, 2026, indicated that Stellantis was seeking European cash to mitigate tariff-related challenges, suggesting cash-flow stress [1]. Group 3: Communication and Transparency - There was a notable gap of over 90 days between the last earnings call on October 30, 2025, and the February 6 disclosure, during which the company's forward-looking EV narrative remained unchanged despite internal challenges [1]. - The investigation focuses on whether Stellantis' public communications accurately reflected its internal understanding of the viability and valuation of its EV assets during this period [1].

Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ultragenyx investors wh ...

Core Viewpoint - Ralliant Corp. is under investigation due to a significant discrepancy between its adjusted earnings and GAAP earnings for Q4 2025, primarily caused by a $1.4 billion goodwill impairment charge, leading to a GAAP loss of $12.10 per share, while adjusted earnings exceeded analyst expectations [1][1][1] Financial Performance - Ralliant reported adjusted earnings per share that surpassed analyst expectations, but GAAP earnings per share reflected a loss of $12.10, indicating a swing of over $14 per share due to the impairment charge [1][1][1] - Revenue for the quarter was $554.6 million, aligning closely with the FactSet estimate of $545.4 million, suggesting that the core revenue performance was not the cause of the earnings divergence [1][1][1] Regulatory Scrutiny - The Securities and Exchange Commission (SEC) has increased scrutiny on non-GAAP earnings metrics, cautioning companies against presenting adjusted figures more prominently than GAAP results [1][1][1] - SEC guidance emphasizes that large reconciling items between GAAP and non-GAAP results require clear and specific disclosure, which is a focal point of the investigation into Ralliant [1][1][1] Market Reaction - Following the earnings disclosure, Ralliant's stock declined over 25% the next day, with shares opening sharply lower and remaining depressed throughout the session, indicating a market focus on the GAAP loss rather than the adjusted earnings beat [1][1][1]

Gartner Shares Sink to 52-Week Low After Q4 Revenue and 2026 Outlook Misses [Accessibility Statement] Skip NavigationNYSE: ITNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Gartner, Inc. (NYSE: IT) following the company's fourth quarter 2025 earnings release that sent shares to their lowest level in a year. [Investors who purchased Gartner stock and experienced losses may click here for more information.]According to data compiled from Yahoo Finance, Investing.com, GuruFocus, ...

Core Insights - Keurig Dr Pepper is launching over 35 new beverage varieties in 2026, focusing on bold flavors, nostalgic favorites, zero sugar options, and expanded energy offerings [1][2][3] - The company aims to meet consumer demand for diverse beverage choices throughout the day, with a significant percentage of Americans and Gen Z actively trying new beverages each month [1][2] - Innovations include limited-time offerings and modern twists on classic flavors, catering to current trends and seasonal celebrations [1][2][3] Product Innovations - New flavors include Dr Pepper Creamy Coconut, A&W Root Beer Float, and Snapple Two Hundred FifTEA Party, designed to appeal to nostalgic and contemporary tastes [1][2] - The Snapple brand is undergoing a visual refresh to enhance shelf appeal and highlight real ingredients [2][3] - Mott's is introducing a Zero Sugar juice drink line, expanding options for health-conscious consumers [3] Market Trends - Zero sugar beverages are significantly outpacing regular varieties, driving six times more dollar growth, indicating a shift in consumer preferences towards healthier options [2][3] - Citrus flavors remain popular among younger consumers, with new products like Bai Barù Blood Orange and 7UP Endless Summer Mandarin Orange being introduced [3] Energy Beverage Segment - The energy drink market is seeing new entries such as GHOST Energy and C4 Energy, featuring innovative flavors and formats to attract younger consumers [2][3] - Black Rifle Energy and Bloom Sparkling Energy are also expanding their offerings with unique flavor profiles [3] Company Overview - Keurig Dr Pepper operates with over 125 brands and reported annual revenues exceeding $15 billion, holding leadership positions in various beverage categories [2][3] - The company emphasizes a commitment to innovation and sustainability, aiming to enhance beverage experiences while positively impacting communities and the environment [2][3]

Core Insights - Hagens Berman is investigating BellRing Brands, Inc. (NYSE: BRBR) for alleged securities fraud related to misleading statements about sales growth drivers [1] - The lawsuit claims that BellRing's reported sales growth was artificially inflated due to retailers hoarding inventory, leading to a significant drop in share price when the truth was revealed [1] Company Allegations - The lawsuit alleges that BellRing and its executives misled investors regarding the sustainability and drivers of its sales growth, as well as the competitive landscape affecting demand for its products [1] - Key admissions from BellRing's CFO indicated that retailers were hoarding inventory to avoid stock shortages, which was downplayed as a non-issue for consumption [1] Financial Impact - Following the release of disappointing Q3 2025 financial results, BellRing's share price fell by $17.46, a decrease of 33% [1] - The lawsuit claims that the strong sales reported during the class period were not reflective of actual consumer demand but rather due to temporary inventory stockpiling by retailers [1] Next Steps for Investors - Investors who suffered losses from BRBR shares purchased between November 19, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the lead plaintiff deadline of March 23, 2026 [1]

Core Viewpoint - Health Catalyst has appointed Ben Albert as the new CEO, effective February 12, 2026, to enhance operational efficiency, clinical quality, and consumer experience in healthcare [1] Leadership Changes - Ben Albert, previously President and COO, has taken over from Dan Burton, who will remain with the company as a strategic advisor [1] - The Board of Directors will be reduced to five members by the 2026 Annual Meeting, with several directors stepping down [1] Strategic Focus - Albert aims to streamline operations and align resources with high-return priorities to improve financial performance [1] - The company plans to leverage its technology and expertise to help clients manage costs and improve clinical quality [1] Board Composition - Dawn Smith and Duncan Gallagher have stepped down from the Board, with John Kane set to leave on April 1, 2026 [1] - Matt Arens has been named Chair of the Nominating and Corporate Governance Committee, while Julie Larson-Green continues as Chair of the Compensation Committee [1] Company Background - Health Catalyst is a leading provider of data and analytics technology and services, serving over 1,100 organizations globally [2] - The company focuses on transforming complex healthcare data into actionable insights, contributing to measurable improvements in clinical, financial, and operational outcomes [2]